Sugi Predict

Sugi Predict / Targets / PDE10A

PDE10A

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A · Q9Y233 · PDE10A on Sugi Atlas →

194,032 patent compounds predicted against PDE10A, 93,922 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL102733 SCHEMBL102733 0.69 17/20
SCHEMBL102580 SCHEMBL102580 0.61 17/20
SCHEMBL111344 SCHEMBL111344 0.39 17/20
SCHEMBL147534 SCHEMBL147534 0.66 16/20
SCHEMBL148979 SCHEMBL148979 0.65 16/20
SCHEMBL150270 SCHEMBL150270 0.65 16/20
SCHEMBL130076 SCHEMBL130076 0.55 16/20
SCHEMBL147885 SCHEMBL147885 0.75 15/20
SCHEMBL150502 SCHEMBL150502 0.75 15/20
SCHEMBL149447 SCHEMBL149447 0.73 15/20
Ethaverine Ethaverine (SCHEMBL25606) 0.72 15/20
Dimethylamine Dimethylamine (SCHEMBL150792) 0.72 15/20
SCHEMBL147393 SCHEMBL147393 0.70 15/20
Papaverine Papaverine (SCHEMBL34702) 1.00 14/20
SCHEMBL151819 SCHEMBL151819 0.77 14/20
SCHEMBL150791 SCHEMBL150791 0.67 14/20
SCHEMBL129950 SCHEMBL129950 0.58 14/20
SCHEMBL127922 SCHEMBL127922 0.52 14/20
SCHEMBL101761 SCHEMBL101761 0.50 14/20
Papaverine Papaverine (SCHEMBL121268) 1.00 13/20

Clinical trials — most relevant to PDE10A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis PHASE4COMPLETED
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes PHASE4COMPLETED
Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol? PHASE4COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage PHASE3NOT_YET_RECRUITING
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer PHASE3RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT) PHASE2COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients PHASE1/PHASE2COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063 PHASE1COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram PHASE1COMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children nanCOMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED
Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia nanUNKNOWN
Endurance Performance at Altitude nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE10A binder may also engage these)

ProteinNameSimilarity
STK35 Serine/threonine-protein kinase 35 0.973 landscape →
Q80ZW0 — 0.970 Q80ZW0 →
Q69ZK0 — 0.967 Q69ZK0 →
Q9UPU7 — 0.965 Q9UPU7 →
MALT1 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 0.965 landscape →
Q5QP82 — 0.964 Q5QP82 →
Q9BZ19 — 0.963 Q9BZ19 →
Q496Y0 — 0.963 Q496Y0 →
Q9QYJ6 — 0.961 Q9QYJ6 →
Q3U0J8 — 0.961 Q3U0J8 →
MAP3K15 Mitogen-activated protein kinase kinase kinase 15 0.960 landscape →
Q9WTR8 — 0.960 Q9WTR8 →
A4D1U4 — 0.960 A4D1U4 →
A2RT67 — 0.959 A2RT67 →
Q9NRU3 — 0.958 Q9NRU3 →
Q8N5V2 — 0.958 Q8N5V2 →
Q8TCU6 — 0.958 Q8TCU6 →
Q3LAC4 — 0.958 Q3LAC4 →
A0FI79 — 0.958 A0FI79 →
Q8HXH0 — 0.958 Q8HXH0 →
Q0PGW2 — 0.957 Q0PGW2 →
Q3UHG7 — 0.957 Q3UHG7 →
Q8CA95 — 0.957 Q8CA95 →
Q5RED8 — 0.957 Q5RED8 →
Q2TBA3 — 0.957 Q2TBA3 →
Q9HBU6 — 0.957 Q9HBU6 →
Q5E9N5 — 0.957 Q5E9N5 →
Q8CHE4 — 0.957 Q8CHE4 →
Q9NRR6 — 0.957 Q9NRR6 →
Q62925 — 0.957 Q62925 →